Use of sargramostim as maintenance therapy in patients with stage IV melanoma at high risk for systemic recurrence

Melanoma Res. 2007 Aug;17(4):257-9. doi: 10.1097/CMR.0b013e3282c3a71a.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Granulocyte-Macrophage Colony-Stimulating Factor / metabolism
  • Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use*
  • Humans
  • Immune System
  • Immunotherapy / methods*
  • Male
  • Melanoma / drug therapy*
  • Melanoma / pathology*
  • Middle Aged
  • Models, Biological
  • Neoplasm Metastasis
  • Recombinant Proteins
  • Remission Induction
  • Secondary Prevention*
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Recombinant Proteins
  • sargramostim
  • Granulocyte-Macrophage Colony-Stimulating Factor